Loading…
PRED FORTE is a brand name for Prednisolone. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: For short-term treatment of steroid-responsive inflammatory conditions of the eye, after excluding the presence of viral, fungal and bacterial pathogens in adults.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults One to two drops instilled into the conjunctival sac two to four times daily. During the initial 24 to 48 hours the dosing frequency may be safely increased to 2 drops every hour. Care should be taken not to discontinue therapy prematurely.
No overall differences in safety or effectiveness have been observed between elderly and younger patients. Paediatric population The safety and efficacy in paediatric population have not yet been established. No posology can be recommended.
Method of administration Route of administration is by ocular instillation. To reduce possible systemic absorption, it may be recommended that the lacrimal sac be compressed at the medial canthus (punctal occlusion) for 1 minute. This should be performed immediately following the instillation of each drop.
Shake well before use.
The following undesirable effects have been reported following use of Pred Forte. Frequency categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from available data).
Immune system disorders Not known:
Hypersensitivity, Urticaria Nervous system disorders Not known: Headache Eye disorders Not known: Intraocular pressure increased* Cataract (including subcapsular)* Eye penetration (scleral or corneal perforation)* Foreign body sensation Ocular infection (including bacterial*, fungal*, and viral* infections) Ocular stinging Eye irritation Eye pain Ocular hyperemia Vision blurred* /Visual impairment Mydriasis Eyelid ptosis Gastrointestinal disorders Not known: Dysgeusia Skin and subcutaneous tissue disorders Not known: Pruritus, Rash Systemic: extensive topical use of corticosteroids may lead to systemic side effects*.
4 for further information. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Acute purulent infections of the eye may be masked or enhanced by the use of topical steroids. Pred Forte contains no antimicrobial agent. If infection is present, appropriate measures must be taken to counteract the infective organisms.
Prolonged use may also suppress the host immune response and thus increase the hazard of secondary ocular infections. Fungal infections of the cornea have been reported coincidentally with long-term steroid application and fungal invasion may be suspected in any persistent corneal ulceration where a steroid has been used, or is in use.
Various ocular diseases and long-term use of topical corticosteroids have been known to cause corneal or scleral thinning. Use of topical corticosteroids in the presence of thin corneal or scleral tissue may lead to perforation. The preservative in Pred Forte, benzalkonium chloride, may be absorbed by and cause discoloration of soft contact lenses.
Patients wearing soft contact lenses should be instructed to remove contact lenses prior to administration of the solution and wait at least 15 minutes after instilling Pred Forte before reinserting soft contact lenses. Use of intraocular steroids may prolong the course and may exacerbate the severity of many viral infections on the eye (including herpes simplex).
Patients with a history of herpes simplex keratitis should be treated with caution. Use of steroid medication in the presence of stromal herpes simplex requires caution and should be followed by frequent, mandatory, slit-lamp microscopy.
Prolonged use of topical corticosteroids may cause an increase in intraocular pressure in certain individuals. This may result in glaucoma with damage to the optic nerve with resultant defects in visual acuity and visual fields. Steroids should be used with caution in the presence of glaucoma.
It is advisable that intraocular pressure be checked frequently during treatment with Pred Forte. Eye drops containing corticosteroids should not be used for more than 10 days except under strict ophthalmic supervision with regular checks for intraocular pressure.
Acute untreated purulent ocular infections. Acute superficial herpes simplex (dendritic keratitis); vaccinia, varicella and most other viral diseases of the cornea and conjunctiva. Fungal diseases of the eye. Mycobacterial infection such as tuberculosis of the eye.
1.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Prednisolone in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Posterior subcapsular cataract formation has been reported after heavy or protracted use of topical ophthalmic corticosteroids. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.
2). The possibility of adrenal suppression should be considered with prolonged, frequent, use of high dose topical steroids, particularly in infants and children. To prevent eye injury or contamination, care should be taken to avoid touching the bottle tip to the eye or to any other surface.
Visual disturbance Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR) which have been reported after use of systemic and topical corticosteroids.